<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>YCT-529: Advancing Male Contraception - Praise Ogwuche</title>
    <link rel="stylesheet" href="css/styles.css">
    <!-- Font Awesome for icons -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <!-- Google Fonts -->
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&family=Merriweather:wght@300;400;700&display=swap" rel="stylesheet">
    <meta name="description" content="Capstone research project exploring YCT-529, a non-hormonal male contraceptive targeting retinoic acid receptor alpha (RARα)">
</head>
<body>
    <!-- Header Section -->
    <!-- Elevated Header Section -->
    <header class="modern-header">
        <div class="header-background">
            <div class="animated-wave"></div>
            <div class="animated-wave wave-2"></div>
            <div class="animated-wave wave-3"></div>
        </div>
        
        <div class="header-content">
            <div class="header-title-container">
                <h1 class="main-title">Advancing Male Contraception</h1>
                <div class="title-decoration">
                    <span class="decoration-dot"></span>
                    <span class="decoration-line"></span>
                    <span class="decoration-dot"></span>
                </div>
                <p class="subtitle">YCT-529: A Promising Non-Hormonal Approach</p>
            </div>
            
            <div class="header-badges">
                <span class="badge">
                    <i class="fas fa-university"></i>
                    Minerva University
                </span>
                <span class="badge">
                    <i class="fas fa-graduation-cap"></i>
                    Capstone Project
                </span>
                <span class="badge">
                    <i class="fas fa-calendar-alt"></i>
                    2025
                </span>
            </div>
        </div>
    </header>

    <!-- Elevated Navigation Bar -->
    <nav class="modern-nav">
        <div class="nav-container">
            <div class="nav-logo">
                <span>Praise Ogwuche</span>
            </div>
            <div class="nav-links desktop-nav">
                <a href="#overview" class="nav-link active">
                    <span class="link-icon"><i class="fas fa-chart-bar"></i></span>
                    <span class="link-text">Overview</span>
                </a>
                <a href="#literature" class="nav-link">
                    <span class="link-icon"><i class="fas fa-book"></i></span>
                    <span class="link-text">Literature Review</span>
                </a>
                <a href="#research" class="nav-link">
                    <span class="link-icon"><i class="fas fa-flask"></i></span>
                    <span class="link-text">Research Paper</span>
                </a>
                <a href="#findings" class="nav-link">
                    <span class="link-icon"><i class="fas fa-lightbulb"></i></span>
                    <span class="link-text">Key Findings</span>
                </a>
                <a href="#about" class="nav-link">
                    <span class="link-icon"><i class="fas fa-user"></i></span>
                    <span class="link-text">About</span>
                </a>
            </div>
            <div class="mobile-menu-toggle">
                <span class="toggle-line"></span>
                <span class="toggle-line"></span>
                <span class="toggle-line"></span>
            </div>
        </div>
        <div class="mobile-nav">
            <a href="#overview" class="mobile-nav-link">
                <i class="fas fa-chart-bar"></i>
                <span>Overview</span>
            </a>
            <a href="#literature" class="mobile-nav-link">
                <i class="fas fa-book"></i>
                <span>Literature Review</span>
            </a>
            <a href="#research" class="mobile-nav-link">
                <i class="fas fa-flask"></i>
                <span>Research Paper</span>
            </a>
            <a href="#findings" class="mobile-nav-link">
                <i class="fas fa-lightbulb"></i>
                <span>Key Findings</span>
            </a>
            <a href="#about" class="mobile-nav-link">
                <i class="fas fa-user"></i>
                <span>About</span>
            </a>
        </div>
    </nav>

    <main>
        <!-- Overview Section -->
<!-- Modified Executive Summary section -->
        <section id="overview" class="section">
            <div class="container">
                <div class="executive-header">
                    <h2>Executive Summary</h2>
                    <p class="executive-tagline">YCT-529: A non-hormonal approach to male contraception</p>
                </div>
                
                <div class="executive-grid">
                    <div class="executive-card">
                        <div class="card-number">01</div>
                        <h3>Challenge</h3>
                        <p>Male contraception remains limited, with no widely available oral options. Current approaches often rely on hormonal methods with systemic side effects.</p>
                        <div class="stat-highlight">
                            <span class="stat-number">0</span>
                            <span class="stat-label">FDA-approved male oral contraceptives</span>
                        </div>
                    </div>
                    
                    <div class="executive-card">
                        <div class="card-number">02</div>
                        <h3>Innovation</h3>
                        <p>YCT-529 selectively inhibits retinoic acid receptor alpha (RARα), disrupting spermatogenesis without affecting testosterone.</p>
                        <div class="stat-highlight">
                            <span class="stat-number">99%</span>
                            <span class="stat-label">Reduction in sperm production in mice</span>
                        </div>
                    </div>
                    
                    <div class="executive-card">
                        <div class="card-number">03</div>
                        <h3>Research Approach</h3>
                        <p>A comprehensive study combining literature review and advanced pharmacokinetic modeling across diverse populations.</p>
                        <div class="stat-highlight">
                            <span class="stat-number">16K</span>
                            <span class="stat-label">Virtual participants in PK simulations</span>
                        </div>
                    </div>
                </div>
                
                <div class="executive-papers">
                    <div class="paper-card">
                        <div class="paper-icon"><i class="fas fa-book"></i></div>
                        <h3>Literature Review</h3>
                        <p>Analysis of YCT-529's mechanism of action, preclinical efficacy, and safety profile.</p>
                        <div class="key-finding">
                            <i class="fas fa-check-circle"></i>
                            <span>4-6 weeks to full fertility restoration post-treatment</span>
                        </div>
                        <a href="pdfs/Final Literature Review Capstone.pdf" class="btn primary-btn" target="_blank">Read Full Review</a>
                    </div>
                    
                    <div class="paper-card">
                        <div class="paper-icon"><i class="fas fa-chart-line"></i></div>
                        <h3>Pharmacokinetic Research</h3>
                        <p>Computational modeling of YCT-529's absorption, metabolism, and elimination profiles.</p>
                        <div class="key-finding">
                            <i class="fas fa-check-circle"></i>
                            <span>Significant ethnic differences in drug metabolism</span>
                        </div>
                        <a href="pdfs/Final Research Capstone.pdf" class="btn secondary-btn" target="_blank">Read Full Research</a>
                    </div>
                </div>
                
                <div class="molecule-visualization">
                    <img src="img/molecule-structure.png" alt="YCT-529 Molecular Structure" class="molecule-image">
                    <div class="molecule-caption">
                        <h4>YCT-529 Molecular Structure</h4>
                        <p>4-[5-[2,2-dimethyl-4-(4-methylphenyl)chromen-6-yl]-1H-pyrrol-2-yl]benzoic acid</p>
                    </div>
                </div>
            </div>
        </section>
        
        <div class="section-divider"></div>

        <!-- Literature Review Section -->
        <!-- Enhanced Literature Review Section -->
        <section id="literature" class="section bg-light">
            <div class="container">
                <h2 class="section-title">Literature Review</h2>
                <p class="scientific-subtitle">Molecular mechanisms, signaling pathways, and contraceptive efficacy of YCT-529</p>
                
                <!-- Scientific Research Cards Row -->
                <div class="scientific-grid">
                    <!-- Retinoic Acid Signaling Card -->
                    <div class="scientific-card">
                        <div class="card-header">
                            <div class="card-icon">
                                <i class="fas fa-dna"></i>
                            </div>
                            <h3>Retinoic Acid Signaling in Spermatogenesis</h3>
                        </div>
                        <div class="card-content">
                            <ul class="scientific-points">
                                <li><span class="highlight">Vitamin A derivative</span> essential for gene regulation via RAR-RXR heterodimers</li>
                                <li>Activates <span class="highlight">Stra8</span> and <span class="highlight">Kit</span> genes essential for spermatogonial differentiation</li>
                                <li>Gradient patterns regulate <span class="highlight">spatiotemporal progression</span> of spermatogenic cycle</li>
                                <li>Pulsatile release (every 8.6 days) drives synchronized differentiation</li>
                                <li>Critical for meiotic initiation through <span class="highlight">chromatin remodeling</span> and repression of <span class="highlight">NANOS2</span></li>
                            </ul>
                            <div class="data-point">
                                <span class="data-label">Key Enzymes:</span>
                                <span class="data-value">ALDH1A1, ALDH1A2, RDH10</span>
                            </div>
                            <button class="btn primary-btn modal-trigger" data-modal="signaling-modal">View Detailed Pathway</button>
                        </div>
                    </div>
                    
                    <!-- Molecular Structure Card -->
                    <div class="scientific-card">
                        <div class="card-header">
                            <div class="card-icon">
                                <i class="fas fa-flask"></i>
                            </div>
                            <h3>Molecular Structure & Antagonist Mechanism</h3>
                        </div>
                        <div class="card-content">
                            <ul class="scientific-points">
                                <li>IUPAC: <span class="highlight">4-[5-[2,2-dimethyl-4-(4-methylphenyl)chromen-6-yl]-1H-pyrrol-2-yl]benzoic acid</span></li>
                                <li>Molecular weight: <span class="highlight">435.5 g/mol</span>, LogP: <span class="highlight">5.706</span></li>
                                <li>Rigid fused-ring system enhances <span class="highlight">RARα selectivity</span> (K<sub>i</sub> = 1.5 nM vs. 898 nM for RARβ)</li>
                                <li>Stabilizes RARα in inactive conformation, preventing <span class="highlight">coactivator recruitment</span></li>
                                <li>Promotes <span class="highlight">NCOR1/NCOR2</span> association and maintains <span class="highlight">histone deacetylation</span></li>
                            </ul>
                            <div class="data-point">
                                <span class="data-label">Binding Affinity:</span>
                                <span class="data-value">K<sub>i</sub> = 1.5 nM (RARα)</span>
                            </div>
                            <button class="btn primary-btn modal-trigger" data-modal="structure-modal">View Molecular Structure</button>
                        </div>
                    </div>
                    
                    <!-- Pharmacokinetics Card -->
                    <div class="scientific-card">
                        <div class="card-header">
                            <div class="card-icon">
                                <i class="fas fa-chart-line"></i>
                            </div>
                            <h3>Pharmacokinetics & ADME Properties</h3>
                        </div>
                        <div class="card-content">
                            <ul class="scientific-points">
                                <li>Half-life: <span class="highlight">11 hours</span> with sustained testicular accumulation</li>
                                <li>High plasma protein binding (<span class="highlight">~98.8%</span>) with moderate oral bioavailability</li>
                                <li>Primary metabolism via <span class="highlight">CYP3A4</span>, <span class="highlight">CYP2C8</span>, and <span class="highlight">CYP2C9</span></li>
                                <li>Phase II conjugation through <span class="highlight">UGT1A1/UGT2B7</span> (glucuronidation) and <span class="highlight">SULT1E1</span> (sulfation)</li>
                                <li>C<sub>max</sub>: <span class="highlight">2.1 μM</span> with delayed biliary excretion</li>
                            </ul>
                            <div class="data-point">
                                <span class="data-label">Dosing Range:</span>
                                <span class="data-value">10-20 mg/kg/day</span>
                            </div>
                            <button class="btn primary-btn modal-trigger" data-modal="pk-modal">View PK Profile</button>
                        </div>
                    </div>
                    
                    <!-- Preclinical Results Card -->
                    <div class="scientific-card">
                        <div class="card-header">
                            <div class="card-icon">
                                <i class="fas fa-vial"></i>
                            </div>
                            <h3>Preclinical Efficacy & Safety</h3>
                        </div>
                        <div class="card-content">
                            <ul class="scientific-points">
                                <li><span class="highlight">99% reduction</span> in sperm production in murine models</li>
                                <li>Complete infertility achieved within <span class="highlight">4 weeks</span> of treatment</li>
                                <li>Full fertility recovery <span class="highlight">4-6 weeks</span> post-withdrawal</li>
                                <li>No effect on <span class="highlight">testosterone levels</span> or sexual function</li>
                                <li><span class="highlight">100% suppression</span> of sperm production in non-human primates</li>
                            </ul>
                            <div class="data-point">
                                <span class="data-label">Adverse Effects:</span>
                                <span class="data-value">No systemic toxicity detected</span>
                            </div>
                            <button class="btn primary-btn modal-trigger" data-modal="preclinical-modal">View Complete Data</button>
                        </div>
                    </div>
                </div>
                
                <!-- Clinical Development Card -->
                <div class="clinical-dev-card">
                    <div class="clinical-header">
                        <h3><i class="fas fa-microscope"></i> Current Clinical Development</h3>
                    </div>
                    <div class="clinical-content">
                        <div class="clinical-phases">
                            <div class="phase active">
                                <div class="phase-dot"></div>
                                <div class="phase-info">
                                    <h4>Phase 1</h4>
                                    <p>Ongoing in London (NCT06094283) - Safety, tolerability & PK in healthy males</p>
                                </div>
                            </div>
                            <div class="phase">
                                <div class="phase-dot"></div>
                                <div class="phase-info">
                                    <h4>Phase 1b/2a</h4>
                                    <p>Planned (NCT06542237) - Extended safety & preliminary efficacy</p>
                                </div>
                            </div>
                            <div class="phase">
                                <div class="phase-dot"></div>
                                <div class="phase-info">
                                    <h4>Phase 2b</h4>
                                    <p>Projected 2026 - Contraceptive efficacy & partner safety</p>
                                </div>
                            </div>
                            <div class="phase">
                                <div class="phase-dot"></div>
                                <div class="phase-info">
                                    <h4>Phase 3</h4>
                                    <p>Timeline TBD - Large-scale efficacy & long-term safety</p>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Graphical Abstract Section -->
                <div class="graphical-abstract-section">
                    <h3 class="abstract-title">Graphical Abstract</h3>
                    <div class="abstract-container">
                        <img src="img/graphical-abstract.png" alt="YCT-529 Graphical Abstract" class="abstract-image">
                        <div class="abstract-caption">
                            <p>Comprehensive summary of YCT-529's mechanism, preclinical results, and comparison to existing male contraceptives. The non-hormonal RAR-α antagonism provides a targeted approach with high efficacy and reversibility.</p>
                        </div>
                    </div>
                    <div class="button-center">
                        <a href="pdfs/Final Literature Review Capstone.pdf" class="btn secondary-btn" target="_blank">
                            <span>Read Full Literature Review</span>
                            <i class="fas fa-arrow-right"></i>
                        </a>
                    </div>
                </div>
                
                <!-- Comparison Table -->
                <div class="comparison-section">
                    <h3 class="comparison-title">Contraceptive Method Comparison</h3>
                    <div class="table-responsive">
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Parameter</th>
                                    <th>YCT-529</th>
                                    <th>Hormonal Methods</th>
                                    <th>Condoms</th>
                                    <th>Vasectomy</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Mechanism</td>
                                    <td>RARα antagonism</td>
                                    <td>HPG axis suppression</td>
                                    <td>Physical barrier</td>
                                    <td>Surgical sperm blockage</td>
                                </tr>
                                <tr>
                                    <td>Efficacy (%)</td>
                                    <td>~99% (preclinical)</td>
                                    <td>94-98%</td>
                                    <td>85-98%</td>
                                    <td>99.7%</td>
                                </tr>
                                <tr>
                                    <td>Reversibility</td>
                                    <td>4-6 weeks</td>
                                    <td>3-6 months</td>
                                    <td>Immediate</td>
                                    <td>Limited/Surgical</td>
                                </tr>
                                <tr>
                                    <td>Hormone Effects</td>
                                    <td>None</td>
                                    <td>Significant</td>
                                    <td>None</td>
                                    <td>None</td>
                                </tr>
                                <tr>
                                    <td>Administration</td>
                                    <td>Daily oral</td>
                                    <td>Varies (gel, injection)</td>
                                    <td>Per-use</td>
                                    <td>One-time procedure</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>
            
            <!-- Modals -->
            <div class="modal" id="signaling-modal">
                <div class="modal-content">
                    <span class="close-button">&times;</span>
                    <h2>Retinoic Acid Signaling Pathway</h2>
                    <div class="modal-body">
                        <div class="pathway-diagram">
                            <img src="img/ra-pathway.png" alt="Retinoic Acid Signaling Pathway" class="modal-image">
                        </div>
                        <h3>Key Molecular Interactions:</h3>
                        <ol class="scientific-list">
                            <li>Retinol (ROL) is oxidized to retinal by RDH10 in Sertoli cells</li>
                            <li>Retinal is converted to retinoic acid (RA) by ALDH1A1 and ALDH1A2</li>
                            <li>RA binds to RAR-RXR heterodimers at retinoic acid response elements (RAREs)</li>
                            <li>This complex recruits coactivators (NCOA1, NCOA2) and displaces corepressors (NCOR1, NCOR2)</li>
                            <li>Histone acetylation by HATs promotes chromatin relaxation and gene activation</li>
                            <li>Transcription of Stra8, Kit, and other genes initiates meiosis and germ cell differentiation</li>
                        </ol>
                        <h3>Gene Expression Dynamics:</h3>
                        <ul class="gene-list">
                            <li><strong>Stra8:</strong> Critical for meiotic initiation, activated directly by RA</li>
                            <li><strong>Kit:</strong> Promotes spermatogonial proliferation and differentiation</li>
                            <li><strong>NANOS2:</strong> Inhibits meiosis entry, downregulated by RA signaling</li>
                            <li><strong>Rec8:</strong> Essential for chromosome synapsis during meiosis</li>
                            <li><strong>Dmc1:</strong> Required for homologous recombination</li>
                        </ul>
                        <p class="modal-note">YCT-529 blocks this signaling cascade by binding to RARα, preventing RA binding and maintaining corepressor association, thus inhibiting the transcription of genes essential for spermatogenesis.</p>
                    </div>
                </div>
            </div>
            
            <div class="modal" id="structure-modal">
                <div class="modal-content">
                    <span class="close-button">&times;</span>
                    <h2>Molecular Structure and Binding Mechanism</h2>
                    <div class="modal-body">
                        <div class="structure-comparison">
                            <div class="structure-item">
                                <h3>YCT-529 Chemical Structure</h3>
                                <img src="img/molecule-structure.png" alt="YCT-529 Molecular Structure" class="modal-image">
                                <p>4-[5-[2,2-dimethyl-4-(4-methylphenyl)chromen-6-yl]-1H-pyrrol-2-yl]benzoic acid</p>
                            </div>
                            <div class="structure-item">
                                <h3>RARα Binding Pocket Interaction</h3>
                                <!-- Replaced with text description since binding-pocket.png is missing -->
                                <div class="placeholder-image">
                                    <i class="fas fa-microscope fa-4x"></i>
                                    <p>Binding pocket visualization</p>
                                </div>
                                <p>YCT-529 in the RARα ligand-binding domain, showing key interactions with Ser232 and other residues</p>
                            </div>
                        </div>
                        
                        <h3>Structural Features Enhancing Selectivity:</h3>
                        <ul class="feature-list">
                            <li><strong>Chromene Core:</strong> Provides molecular rigidity and hydrophobic interactions</li>
                            <li><strong>Pyrrole Linker:</strong> Enables π-π stacking with aromatic residues in the binding pocket</li>
                            <li><strong>Benzoic Acid Moiety:</strong> Forms critical hydrogen bonds with Ser232 in RARα</li>
                            <li><strong>2,2-Dimethyl Groups:</strong> Enhance metabolic stability and prevent oxidation</li>
                            <li><strong>4-Methylphenyl Substituent:</strong> Occupies hydrophobic pocket, improving binding affinity</li>
                        </ul>
                        
                        <h3>Structural Basis for RARα Selectivity:</h3>
                        <p>YCT-529's high selectivity for RARα (K<sub>i</sub> = 1.5 nM) over RARβ (K<sub>i</sub> = 898 nM) and RARγ (K<sub>i</sub> = 10,618 nM) is primarily due to the unique Ser232 residue in RARα's ligand-binding domain. This residue, replaced by Ala225 in RARβ and Ala234 in RARγ, creates a polar interaction site that stabilizes YCT-529's binding. The benzoic acid moiety forms specific hydrogen bonds with this residue, while the rigid fused-ring system ensures optimal positioning for these interactions.</p>
                    </div>
                </div>
            </div>
            
            <div class="modal" id="pk-modal">
                <div class="modal-content">
                    <span class="close-button">&times;</span>
                    <h2>Pharmacokinetic Profile of YCT-529</h2>
                    <div class="modal-body">
                        <div class="pk-chart">
                            <img src="img/pk-profile.png" alt="YCT-529 Pharmacokinetic Profile" class="modal-image">
                            <p>Plasma concentration-time profile of YCT-529 after oral administration (10 mg/kg) in mice</p>
                        </div>
                        
                        <h3>Key Pharmacokinetic Parameters:</h3>
                        <div class="pk-parameters">
                            <div class="pk-parameter">
                                <div class="parameter-name">C<sub>max</sub></div>
                                <div class="parameter-value">2.1 μM</div>
                                <div class="parameter-description">Maximum plasma concentration</div>
                            </div>
                            <div class="pk-parameter">
                                <div class="parameter-name">T<sub>max</sub></div>
                                <div class="parameter-value">1-3 hours</div>
                                <div class="parameter-description">Time to maximum concentration</div>
                            </div>
                            <div class="pk-parameter">
                                <div class="parameter-name">T<sub>1/2</sub></div>
                                <div class="parameter-value">11 hours</div>
                                <div class="parameter-description">Elimination half-life</div>
                            </div>
                            <div class="pk-parameter">
                                <div class="parameter-name">V<sub>d</sub></div>
                                <div class="parameter-value">2.4 L/kg</div>
                                <div class="parameter-description">Volume of distribution</div>
                            </div>
                            <div class="pk-parameter">
                                <div class="parameter-name">CL</div>
                                <div class="parameter-value">0.15 L/h/kg</div>
                                <div class="parameter-description">Systemic clearance</div>
                            </div>
                            <div class="pk-parameter">
                                <div class="parameter-name">F</div>
                                <div class="parameter-value">42%</div>
                                <div class="parameter-description">Oral bioavailability</div>
                            </div>
                        </div>
                        
                        <h3>ADME Properties:</h3>
                        <ul class="adme-list">
                            <li><strong>Absorption:</strong> Moderate oral bioavailability (42%) with peak plasma levels at 1-3 hours post-dose</li>
                            <li><strong>Distribution:</strong> High plasma protein binding (98.8%) with significant testicular accumulation</li>
                            <li><strong>Metabolism:</strong> Primarily by CYP3A4 (hydroxylation), with additional contributions from CYP2C8 and CYP2C9</li>
                            <li><strong>Excretion:</strong> Predominantly through biliary elimination after Phase II conjugation (glucuronidation via UGT1A1/UGT2B7)</li>
                        </ul>
                        
                        <h3>Predicted Population Differences:</h3>
                        <p>PBPK modeling suggests potential variations in YCT-529 pharmacokinetics across ethnic groups, with East Asians showing higher systemic exposure due to reduced CYP3A4 activity, while Black Americans exhibit more rapid clearance. These differences may necessitate population-specific dosing regimens for optimal contraceptive efficacy.</p>
                    </div>
                </div>
            </div>
            
            <div class="modal" id="preclinical-modal">
                <div class="modal-content">
                    <span class="close-button">&times;</span>
                    <h2>Preclinical Efficacy and Safety Profile</h2>
                    <div class="modal-body">
                        <div class="efficacy-images">
                            <div class="efficacy-image">
                                <img src="img/histology.png" alt="Testicular Histology" class="modal-image">
                                <p>Testicular histology showing disrupted spermatogenesis after YCT-529 treatment</p>
                            </div>
                            <div class="efficacy-image">
                                <!-- Replaced with text description since sperm-count.png is missing -->
                                <div class="placeholder-image">
                                    <i class="fas fa-chart-bar fa-4x"></i>
                                    <p>Sperm count visualization</p>
                                </div>
                                <p>Dose-dependent reduction in sperm count with YCT-529 treatment</p>
                            </div>
                        </div>
                        
                        <h3>Efficacy Data Summary:</h3>
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th>Parameter</th>
                                    <th>Control</th>
                                    <th>10 mg/kg/day</th>
                                    <th>20 mg/kg/day</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Sperm Count (% reduction)</td>
                                    <td>0%</td>
                                    <td>95%</td>
                                    <td>99%</td>
                                </tr>
                                <tr>
                                    <td>Time to Infertility</td>
                                    <td>N/A</td>
                                    <td>4 weeks</td>
                                    <td>2 weeks</td>
                                </tr>
                                <tr>
                                    <td>Recovery Time</td>
                                    <td>N/A</td>
                                    <td>4-6 weeks</td>
                                    <td>6 weeks</td>
                                </tr>
                                <tr>
                                    <td>Testosterone Levels</td>
                                    <td>Baseline</td>
                                    <td>No change</td>
                                    <td>No change</td>
                                </tr>
                                <tr>
                                    <td>Sexual Behavior</td>
                                    <td>Normal</td>
                                    <td>Normal</td>
                                    <td>Normal</td>
                                </tr>
                            </tbody>
                        </table>
                        
                        <h3>Histopathological Findings:</h3>
                        <ul class="histology-list">
                            <li>Disrupted spermatid alignment and release, similar to RARα knockout phenotype</li>
                            <li>Reduced number of late-stage spermatids in seminiferous tubules</li>
                            <li>Preservation of spermatogonial stem cells, ensuring reversibility</li>
                            <li>No observable changes in Leydig or Sertoli cell morphology</li>
                            <li>Absence of inflammatory or necrotic changes in testicular tissue</li>
                        </ul>
                        
                        <h3>Safety Assessment:</h3>
                        <ul class="safety-list">
                            <li>No significant changes in hematology, clinical chemistry, or urinalysis parameters</li>
                            <li>Body weight and food consumption remained within normal ranges</li>
                            <li>No adverse findings in cardiovascular, respiratory, or central nervous system evaluations</li>
                            <li>No evidence of organ toxicity in comprehensive histopathological examination</li>
                            <li>No mutagenic potential in Ames test or chromosomal aberration assays</li>
                        </ul>
                        
                        <h3>Non-Human Primate Data:</h3>
                        <p>Administration of YCT-529 at 10-20 mg/kg/day in non-human primates resulted in complete suppression of sperm production without systemic toxicity, validating findings from murine models and supporting progression to human trials.</p>
                    </div>
                </div>
            </div>
        </section>

        <div class="section-divider"></div>

        <!-- Research Paper Section -->
        <!-- Improved Research Paper Section -->
        <section id="research" class="section">
            <div class="container">
                <h2 class="section-title">Pharmacokinetic Research</h2>
                <p class="scientific-subtitle">Population-specific modeling and simulation of YCT-529 pharmacokinetics</p>
                
                <div class="research-grid">
                    <!-- Methodology Card -->
                    <div class="research-card methodology-card">
                        <div class="card-header">
                            <h3><i class="fas fa-flask"></i> Methodology Overview</h3>
                        </div>
                        <div class="card-content">
                            <p class="card-description">This study employed physiologically based pharmacokinetic (PBPK) modeling to characterize YCT-529's behavior across diverse populations and dosing regimens.</p>
                            
                            <div class="method-steps">
                                <div class="method-step">
                                    <div class="step-icon">
                                        <i class="fas fa-dna"></i>
                                    </div>
                                    <div class="step-content">
                                        <h4>SMILES String Generation</h4>
                                        <p>Molecular structure encoded for computational analysis</p>
                                    </div>
                                </div>
                                
                                <div class="method-step">
                                    <div class="step-icon">
                                        <i class="fas fa-laptop-code"></i>
                                    </div>
                                    <div class="step-content">
                                        <h4>ADMETLab 3.0 Analysis</h4>
                                        <p>Predictions for absorption, distribution, metabolism, excretion, and toxicity</p>
                                    </div>
                                </div>
                                
                                <div class="method-step">
                                    <div class="step-icon">
                                        <i class="fas fa-chart-line"></i>
                                    </div>
                                    <div class="step-content">
                                        <h4>PK-Sim Modeling</h4>
                                        <p>Simulated 16,000 participants across populations and dosing regimens</p>
                                    </div>
                                </div>
                                
                                <div class="method-step">
                                    <div class="step-icon">
                                        <i class="fas fa-check-circle"></i>
                                    </div>
                                    <div class="step-content">
                                        <h4>Validation</h4>
                                        <p>Atazanavir used as reference drug to validate model accuracy</p>
                                    </div>
                                </div>
                            </div>
                            
                            <div class="data-point">
                                <span class="data-label">Computational Tools:</span>
                                <span class="data-value">PK-Sim, ADMETLab 3.0, R Studio</span>
                            </div>
                            
                            <button class="btn primary-btn modal-trigger" data-modal="methodology-modal">View Detailed Methodology</button>
                        </div>
                    </div>
                    
                    <!-- Key Findings Card -->
                    <div class="research-card findings-card">
                        <div class="card-header">
                            <h3><i class="fas fa-lightbulb"></i> Key Findings</h3>
                        </div>
                        <div class="card-content">
                            <div class="findings-grid">
                                <div class="finding-item blue-card">
                                    <div class="finding-icon"><i class="fas fa-bolt"></i></div>
                                    <h4>Rapid Absorption</h4>
                                    <p>YCT-529 showed rapid absorption with Tmax occurring within 1–3 hours and dose-dependent increases in systemic exposure.</p>
                                </div>
                                
                                <div class="finding-item purple-card">
                                    <div class="finding-icon"><i class="fas fa-users"></i></div>
                                    <h4>Population Differences</h4>
                                    <p>East Asians showed the highest systemic retention (Cmax ~500 μg/L at 180 mg), while Black Americans had the lowest (~300 μg/L), consistent with CYP3A4 metabolic variability.</p>
                                </div>
                                
                                <div class="finding-item green-card">
                                    <div class="finding-icon"><i class="fas fa-utensils"></i></div>
                                    <h4>Dietary Impact</h4>
                                    <p>Fasting increased Cmax to ~100 μg/L, while high-fat meals reduced it to ~55 μg/L, suggesting food affects absorption kinetics.</p>
                                </div>
                                
                                <div class="finding-item orange-card">
                                    <div class="finding-icon"><i class="fas fa-clipboard-check"></i></div>
                                    <h4>Model Validation</h4>
                                    <p>Atazanavir pharmacokinetics closely matched clinical data, supporting the validity of the simulation approach.</p>
                                </div>
                            </div>
                            
                            <div class="data-point">
                                <span class="data-label">Statistical Significance:</span>
                                <span class="data-value">p < 0.001 for population differences</span>
                            </div>
                            
                            <button class="btn secondary-btn modal-trigger" data-modal="results-modal">View Detailed Results</button>
                        </div>
                    </div>
                </div>
                
                <div class="research-visuals">
                    <h3 class="visuals-title"><i class="fas fa-chart-area"></i> Data Visualization</h3>
                    
                    <div class="visuals-grid">
                        <!-- Plasma Concentration Card -->
                        <div class="visual-card">
                            <div class="visual-header">
                                <h4>Plasma Concentration Profiles</h4>
                                <span class="visual-badge">Figure 3</span>
                            </div>
                            <div class="visual-image">
                                <img src="img/figures/plasma-concentration.png" alt="Plasma Concentration Profiles">
                                <div class="zoom-overlay">
                                    <i class="fas fa-search-plus"></i>
                                </div>
                            </div>
                            <div class="visual-caption">
                                <p>Plasma concentration-time profiles for YCT-529 at multiple doses across populations. East Asian participants exhibit the highest Cmax, indicating potential metabolic differences affecting clearance.</p>
                                <div class="key-insight">
                                    <i class="fas fa-info-circle"></i>
                                    <span>CYP3A4 expression varies by 40% across ethnic groups</span>
                                </div>
                            </div>
                        </div>
                        
                        <!-- Dietary Effects Card -->
                        <div class="visual-card">
                            <div class="visual-header">
                                <h4>Dietary Effects on Pharmacokinetics</h4>
                                <span class="visual-badge">Figure 5</span>
                            </div>
                            <div class="visual-image">
                                <img src="img/figures/dietary-effects.png" alt="Dietary Effects on Pharmacokinetics">
                                <div class="zoom-overlay">
                                    <i class="fas fa-search-plus"></i>
                                </div>
                            </div>
                            <div class="visual-caption">
                                <p>Impact of dietary conditions on YCT-529 pharmacokinetics. Fasting results in higher peak concentrations compared to fed states.</p>
                                <div class="key-insight">
                                    <i class="fas fa-info-circle"></i>
                                    <span>45% reduction in Cmax with high-fat meal</span>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <div class="research-applications">
                    <h3 class="applications-title">Clinical Implications</h3>
                    
                    <div class="applications-grid">
                        <div class="application-card">
                            <div class="application-icon">
                                <i class="fas fa-pills"></i>
                            </div>
                            <h4>Dosing Recommendations</h4>
                            <p>Population-specific dosing may be required, with East Asian individuals potentially needing lower doses due to higher systemic exposure.</p>
                        </div>
                        
                        <div class="application-card">
                            <div class="application-icon">
                                <i class="fas fa-calendar-alt"></i>
                            </div>
                            <h4>Administration Timing</h4>
                            <p>Consistent timing relative to meals is important, with administration during fasting potentially improving bioavailability.</p>
                        </div>
                        
                        <div class="application-card">
                            <div class="application-icon">
                                <i class="fas fa-vial"></i>
                            </div>
                            <h4>Clinical Trial Design</h4>
                            <p>Stratification by ethnicity and standardization of meal timing should be incorporated into future clinical trials.</p>
                        </div>
                    </div>
                </div>
                
                <div class="button-center">
                    <a href="pdfs/Final Research Capstone.pdf" class="btn research-btn" target="_blank">
                        <span>Read Full Research Paper</span>
                        <i class="fas fa-arrow-right"></i>
                    </a>
                </div>
            </div>
        </section>

        <div class="section-divider"></div>

        <!-- Findings Section -->
        <section id="findings" class="section bg-light">
            <div class="container">
                <h2 class="section-title">Key Findings & Implications</h2>
                
                <div class="timeline-container">
                    <div class="timeline">
                        <div class="timeline-item left">
                            <div class="timeline-content">
                                <h3>Molecular Mechanism</h3>
                                <p>YCT-529 selectively inhibits RAR-α, preventing retinoic acid signaling necessary for spermatogenesis.</p>
                            </div>
                        </div>
                        
                        <div class="timeline-item right">
                            <div class="timeline-content">
                                <h3>Preclinical Efficacy</h3>
                                <p>99% reduction in sperm production in murine models with full fertility restoration within 4 weeks post-treatment.</p>
                            </div>
                        </div>
                        
                        <div class="timeline-item left">
                            <div class="timeline-content">
                                <h3>Population Pharmacokinetics</h3>
                                <p>Significant differences in drug metabolism across racial groups suggest the need for personalized dosing strategies.</p>
                            </div>
                        </div>
                        
                        <div class="timeline-item right">
                            <div class="timeline-content">
                                <h3>Dietary Considerations</h3>
                                <p>Food intake affects YCT-529 absorption, with fasting increasing peak concentrations while high-fat meals reduce them, suggesting administration timing matters.</p>
                            </div>
                        </div>
                        
                        <div class="timeline-item left">
                            <div class="timeline-content">
                                <h3>Clinical Potential</h3>
                                <p>YCT-529 represents a promising non-hormonal alternative with fewer side effects than hormonal methods, potentially transforming male contraception.</p>
                            </div>
                        </div>
                        
                        <div class="timeline-item right">
                            <div class="timeline-content">
                                <h3>Future Research</h3>
                                <p>Clinical trials are needed to confirm efficacy and assess dietary effects on absorption, with Phase 1 trials currently underway in London.</p>
                            </div>
                        </div>
                    </div>
                </div>
                
            <!-- Simplified Implications for Male Contraception Section -->
            <h3 class="subsection-title">Implications for Male Contraception</h3>

            <div class="three-column">
                <div class="implication-card">
                    <div class="icon-container blue-icon">
                        <i class="fas fa-pills"></i>
                    </div>
                    <h4>Medical Innovation</h4>
                    <p>YCT-529 represents a novel approach to male contraception, expanding options beyond hormonal methods and physical barriers.</p>
                </div>
                
                <div class="implication-card">
                    <div class="icon-container purple-icon">
                        <i class="fas fa-balance-scale"></i>
                    </div>
                    <h4>Gender Equity</h4>
                    <p>Expanding male contraceptive options promotes shared responsibility in reproductive health and family planning decisions.</p>
                </div>
                
                <div class="implication-card">
                    <div class="icon-container green-icon">
                        <i class="fas fa-chart-line"></i>
                    </div>
                    <h4>Public Health Impact</h4>
                    <p>Increased contraceptive options could reduce unintended pregnancies, improving health outcomes and economic stability.</p>
                </div>
            </div>
        </section>

        <div class="section-divider"></div>

        <!-- Improved About the Project Section -->
        <section id="about" class="section">
            <div class="container">
                <h2 class="section-title">About the Project</h2>
                
                <div class="about-grid">
                    <!-- Author Card -->
                    <div class="about-card">
                        <div class="card-icon">
                            <i class="fas fa-user-graduate"></i>
                        </div>
                        <h3>Author</h3>
                        <div class="author-info">
                            <h4 class="author-name">Praise Ogwuche</h4>
                            <p>Minerva University</p>
                            <p>Class of 2025</p>
                        </div>
                    </div>
                    
                    <!-- Capstone Project Card -->
                    <div class="about-card">
                        <div class="card-icon">
                            <i class="fas fa-book"></i>
                        </div>
                        <h3>Capstone Project</h3>
                        <div class="project-info">
                            <p>This project represents the culmination of my undergraduate studies at Minerva University.</p>
                            <div class="completion-date">
                                <i class="fas fa-calendar-check"></i>
                                <span>Completed April 2025</span>
                            </div>
                        </div>
                    </div>
                    
                    <!-- Resources Card -->
                    <div class="about-card">
                        <div class="card-icon">
                            <i class="fas fa-link"></i>
                        </div>
                        <h3>Resources</h3>
                        <div class="resources-links">
                            <a href="https://github.com/PraiseOgwuche/YCT-529_WEB" target="_blank" class="resource-link">
                                <i class="fab fa-github"></i>
                                <span>GitHub Repository</span>
                            </a>
                            <a href="pdfs/Capstone Project Executive Summary.pdf" target="_blank" class="resource-link">
                                <i class="fas fa-file-pdf"></i>
                                <span>Executive Summary</span>
                            </a>
                            <a href="pdfs/Final Literature Review Capstone.pdf" target="_blank" class="resource-link">
                                <i class="fas fa-file-pdf"></i>
                                <span>Literature Review PDF</span>
                            </a>
                            <a href="https://medium.com/@praiseogwuche/unlocking-male-contraception-the-science-behind-yct-529-and-retinoic-acid-signaling-441b18e18552" target="_blank" class="resource-link">
                                <i class="fab fa-medium"></i>
                                <span>Literature Review on Medium</span>
                            </a>
                            <a href="pdfs/Final Research Capstone.pdf" target="_blank" class="resource-link">
                                <i class="fas fa-file-pdf"></i>
                                <span>Research Paper PDF</span>
                            </a>
                            <a href="https://medium.com/@praiseogwuche/the-science-of-a-male-birth-control-pill-a-deep-dive-into-yct-529s-pharmacokinetics-b148930022ad" target="_blank" class="resource-link">
                                <i class="fab fa-medium"></i>
                                <span>Research Paper on Medium</span>
                            </a>
                            <a href="pdfs/Research Appendices.pdf" target="_blank" class="resource-link">
                                <i class="fas fa-file-alt"></i>
                                <span>Research Appendices</span>
                            </a>
                        </div>
                    </div>
                </div>
                
                <!-- Acknowledgments Section -->
                <div class="acknowledgments">
                    <div class="acknowledgments-card">
                        <h3><i class="fas fa-award"></i> Acknowledgments</h3>
                        <p>I would like to thank Professor Stan for their guidance and mentorship throughout this project. Additionally, I appreciate the support from Minerva University and all those who provided feedback and assistance.</p>
                        <p>Special thanks to the research community advancing male contraception and contributing to reproductive health equity.</p>
                    </div>
                </div>
            </div>
        </section>
    </main>

    <!-- Modal components -->
    <div class="modal" id="structure-modal">
        <div class="modal-content">
            <span class="close-button">&times;</span>
            <h2>Chemical Composition and Structure of YCT-529</h2>
            <div class="modal-body">
                <p>YCT-529, chemically known as 4-[5-[2,2-dimethyl-4-(4-methylphenyl)chromen-6-yl]-1H-pyrrol-2-yl]benzoic acid, is a highly selective non-hormonal oral male contraceptive targeting retinoic acid receptor alpha (RARα).</p>
                
                <div class="image-container">
                    <img src="img/molecule-structure.png" alt="Chemical structure of YCT-529" class="modal-image">
                </div>
                
                <p>To read the complete analysis of YCT-529's chemical structure and mechanism of action, please refer to the full literature review:</p>
                
                <div class="button-center">
                    <a href="pdfs/Final Literature Review Capstone.pdf" class="btn primary-btn" target="_blank">
                        View in Literature Review
                    </a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal" id="signaling-modal">
        <div class="modal-content">
            <span class="close-button">&times;</span>
            <h2>Retinoic Acid Signaling in Spermatogenesis</h2>
            <div class="modal-body">
                <p>Retinoic acid (RA) plays a crucial role in regulating spermatogenesis. As a metabolite of vitamin A, it activates nuclear receptors that control gene expression patterns essential for germ cell development, differentiation, and maturation.</p>
                
                <p>RA signaling coordinates the differentiation of spermatogonia, initiates meiosis, and ensures proper sperm maturation throughout the spermatogenic cycle.</p>
                
                <p>For a comprehensive exploration of RA signaling in spermatogenesis, please refer to the full literature review:</p>
                
                <div class="button-center">
                    <a href="pdfs/Final Literature Review Capstone.pdf#page=20" class="btn primary-btn" target="_blank">
                        View in Literature Review
                    </a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal" id="preclinical-modal">
        <div class="modal-content">
            <span class="close-button">&times;</span>
            <h2>Preclinical Validation of YCT-529</h2>
            <div class="modal-body">
                <p>Preclinical studies have demonstrated YCT-529's efficacy in inhibiting spermatogenesis with a favorable safety profile and full reversibility, positioning it as a promising candidate for male contraception.</p>
                
                <p>Key findings include:</p>
                <ul>
                    <li>99% reduction in sperm production in murine models</li>
                    <li>Full reversibility within 4 weeks post-treatment</li>
                    <li>No effect on testosterone levels or sexual function</li>
                    <li>Pharmacokinetic profile with 11-hour half-life</li>
                </ul>
                
                <p>For detailed analysis of the preclinical studies, please refer to the full literature review:</p>
                
                <div class="button-center">
                    <a href="pdfs/Final Literature Review Capstone.pdf#page=30" class="btn primary-btn" target="_blank">
                        View in Literature Review
                    </a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal" id="methodology-modal">
        <div class="modal-content">
            <span class="close-button">&times;</span>
            <h2>Methodology for Pharmacokinetic Modeling of YCT-529</h2>
            <div class="modal-body">
                <p>This study employed a structured computational workflow to simulate YCT-529's pharmacokinetics using PBPK modeling tools. The methodology included:</p>
                
                <ul>
                    <li>SMILES string generation for molecular representation</li>
                    <li>ADMETLab 3.0 analysis of physicochemical properties</li>
                    <li>PK-Sim modeling across 16,000 virtual participants</li>
                    <li>Validation using Atazanavir as a reference drug</li>
                </ul>
                
                <p>For the complete methodology description, please refer to the full research paper:</p>
                
                <div class="button-center">
                    <a href="pdfs/Final Research Capstone.pdf#page=4" class="btn primary-btn" target="_blank">
                        View in Research Paper
                    </a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal" id="results-modal">
        <div class="modal-content">
            <span class="close-button">&times;</span>
            <h2>Results of YCT-529 Pharmacokinetic Modeling</h2>
            <div class="modal-body">
                <p>The pharmacokinetic modeling of YCT-529 revealed several key findings:</p>
                
                <ul>
                    <li>Rapid absorption with T<sub>max</sub> occurring within 1–3 hours</li>
                    <li>Dose-dependent increases in systemic exposure</li>
                    <li>Significant population differences, with East Asians showing higher systemic retention</li>
                    <li>Dietary intake affecting absorption, with fasting increasing peak concentrations</li>
                </ul>
                
                <p>For detailed results and data visualization, please refer to the full research paper:</p>
                
                <div class="button-center">
                    <a href="pdfs/Final Research Capstone.pdf#page=11" class="btn primary-btn" target="_blank">
                        View in Research Paper
                    </a>
                </div>
            </div>
        </div>
    </div>

    <!-- Footer -->
    <footer>
        <div class="footer-container">
            <div class="footer-content">
                <div class="footer-info">
                    <h3>YCT-529 Capstone Project</h3>
                    <p>Advancing Male Contraception Research</p>
                </div>
                <div class="footer-social">
                    <a href="https://github.com/PraiseOgwuche/YCT-529_WEB" target="_blank"><i class="fab fa-github"></i></a>
                    <a href="#"><i class="fab fa-linkedin"></i></a>
                    <a href="mailto:example@minerva.edu"><i class="fas fa-envelope"></i></a>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2025 Praise Ogwuche. All rights reserved.</p>
            </div>
        </div>
    </footer>

    <script src="js/main.js"></script>
</body>
</html>